Ceribell

Ceribell

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $97M

Overview

Ceribell is a private medical device company headquartered in Sunnyvale, California, focused on transforming the diagnosis and management of patients with serious neurological conditions. Its core technology is a portable, rapidly deployable EEG platform combined with sophisticated AI algorithms, most notably the Clarity® seizure detection algorithm. The company has achieved significant clinical validation with over 135 publications, FDA clearances for neonates through adults, and demonstrated impact on reducing ICU length of stay and improving patient outcomes.

NeurologyCritical CareEmergency MedicineNeonatology

Technology Platform

A point-of-care EEG platform combining rapidly deployable hardware with AI algorithms (Clarity®) for real-time seizure detection and brain monitoring. Includes a secure, FedRAMP High-authorized cloud portal for remote review.

Funding History

4
Total raised:$97M
Series C$50M
Series B$30M
Series A$15M
Seed$2M

Opportunities

Significant growth opportunities exist in expanding within the large U.S.
hospital market, international expansion, and leveraging the core AI platform for new applications like delirium monitoring.
The proven economic value (reduced ICU stays) and strong clinical evidence provide a powerful platform for market penetration.

Risk Factors

Key risks include commercial execution challenges in a cost-conscious hospital environment, ongoing litigation with competitor Natus, the need to secure permanent reimbursement beyond temporary NTAP status, and the constant need to validate and improve AI algorithms across diverse patient populations.

Competitive Landscape

Ceribell competes with traditional conventional EEG services and other portable EEG devices. Its main differentiation lies in its combination of rapid bedside deployment, a clinically validated AI algorithm (Clarity®) with broad age clearance, a strong evidence base demonstrating improved patient outcomes, and a secure, cloud-based platform with FedRAMP High authorization.